相关实验视频

Updated: Jun 7, 2025

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

选择性的BDNF的诺亚 adrenoergic激活由米尔塔扎平因翻译

Viviana Ciraci¹, Letizia Santoni², Enrico Tongiorgi²

¹Department of Life Sciences, University of Trieste, Via Licio Giorgieri, 5 (Q Building), 34127, Trieste, Italy. viviana.ciraci@units.it.

Molecular neurobiology

|November 18, 2024

概括

米尔塔扎通过调节北上腺素受体来增强脑衍生的神经营养因子 (BDNF) 翻译. 这种抗抑郁药是抗抑郁药.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

抗抑郁药,包括米尔塔扎,影响神经变因子,如脑衍生神经变因子 (BDNF).
米尔塔扎因影响BDNF表达的确切机制,特别是其翻译,尚未完全理解.
米尔塔扎平被归类为一种诺拉德能和特定的血清能抗抑郁药 (NaSSA).

研究的目的:

为了研究米尔塔扎如何增强BDNF翻译.
探索血清素和上腺素受体在调解米尔塔扎对BDNF的影响中的作用.
阐明特定的BDNF转录和涉及的信号通路.

主要方法:

使用了人类神经母细胞瘤SH-SY5Y细胞系.
用米尔塔扎激活细胞并测量受体表达 (5HT1A,ADRA2A,ADRB2).
评估内源BDNF水平和BDNF-luciferase记者结构,以分析长3'UTR.长的特定BDNF转录的翻译 (外显子I,IIc,IV,VI).

主要成果:

米尔塔扎 (10微米) 在3小时后增加了内源BDNF的调节.
观察到对exon-IIc-BDNF-long3'UTR-luciferase翻译的选择性增强.
上腺素的释放与增加的BDNF转化相关,通过阻断ADRA2A/ADRB2受体来抑制这种转化.

结论:

米尔塔扎通过诺亚上腺系统增强BDNF转化,特别是外因子IIc变体.
抗抑郁药可以调高ADRA2A和ADRB2受体,同时调低5HT1A受体.
这些发现表明,在米尔塔扎对BDNF的作用中,一种新的机制涉及北上腺素释放和北上腺素受体激活.

关键词:

5HT 5HT 5HT 5HT 5HT 5HT 5HT 5HT 5HT 5HT 5HT 5HT 这就是为什么BDNF是BDNF.米尔塔扎皮因 (Mirtazapine) 是一种药物.没有了,没有了,没有了.这就是SH-SY5YY.

更多相关视频

Real-time Imaging of Axonal Transport of Quantum Dot-labeled BDNF in Primary Neurons

Real-time Imaging of Axonal Transport of Quantum Dot-labeled BDNF in Primary Neurons

Published on: September 15, 2014

An Improved Protocol to Purify and Directly Mono-Biotinylate Recombinant BDNF in a Tube for Cellular Trafficking Studies in Neurons

An Improved Protocol to Purify and Directly Mono-Biotinylate Recombinant BDNF in a Tube for Cellular Trafficking Studies in Neurons

Published on: July 11, 2020

相关概念视频

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Management of Insomnia

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...